Form 4: Moderna CFO James Mock Reports Stock Transactions

Chief Financial Officer of Moderna, James Mock, reports acquisition and disposal of company stock and performance stock units.

Summary

• James Mock, the CFO of Moderna, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• On May 31, 2024, Mock acquired 1,326 performance stock units that converted into common stock and disposed of 7,197 common stock.
• On June 3, 2024, Mock disposed of 691 shares of common stock at a price of $140.7198 per share to cover tax withholding obligations.
• Following these transactions, Mock directly owns 6,506 shares of common stock and 3,978 performance stock units.
• The performance stock units vest in installments, with 25% vesting on May 31, 2024, and the remainder vesting in three equal installments on August 27, 2024, November 27, 2024, and February 27, 2025.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Future Outlook

The remaining performance stock units will vest in three equal installments on August 27, 2024, November 27, 2024 and February 27, 2025.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates transactions by Moderna's CFO, which is typical for executives with stock-based compensation.

Comparison to Industry Standards

• Executive compensation packages often include performance-based stock units that vest over time, aligning executive incentives with company performance, similar to practices at companies like Pfizer and BioNTech.
• The 'sell-to-cover' transaction for tax obligations is a standard practice among publicly traded companies to manage the tax implications of equity compensation, as seen in filings from executives at Johnson & Johnson and Merck.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the 'sell-to-cover' transaction is a standard practice and unlikely to cause significant concern.

Key Dates